PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X, Long Y, Chen B, Tong Y, Shan M, Jia X, Hu C, Liu M, Zhou J, Tang F, Lu H, Chen R, Xu P, Huang W, Ren J, Wan Y, Sun J, Li J, Jin G, Gong L.
Yu X, et al.
J Immunother Cancer. 2022 Oct;10(10):e004590. doi: 10.1136/jitc-2022-004590.
J Immunother Cancer. 2022.
PMID: 36253000
Free PMC article.